Archive

Skip to content The CRC Digest ◆ TRIAL DATA STRATEGIC-1 Trial Defines Optimal Treatment Sequence for RAS/BRAF Wild-Type Metastatic Colorectal Cancer — Signal Transduction and Targeted Therapy The Phase III STRATEGIC-1 trial (NCT01910610) compared different sequences of chemotherapy combined with either anti-EGFR antibodies (cetuximab/panitumumab) or anti-angiogenic drugs (bevacizumab) in patients

Skip to content The CRC Digest ▪ SCREENING Circulating Tumor DNA Before Surgery Predicts Recurrence After Liver Metastasis Resection — Clinical Cancer Research Researchers analyzed blood samples from 116 patients with metastatic colorectal cancer confined to the liver who underwent surgery after chemotherapy. They measured circulating tumor DNA (ctDNA)—fragments of cancer

Skip to content The CRC Digest ◆ TRIAL DATA Perioperative Pembrolizumab Shows High Complete Response Rate in MSI-H/dMMR Localized Colorectal Cancer — Journal of Clinical Oncology Journal of Clinical Oncology. MSI-H/dMMR tumors have defects in DNA repair machinery that make them highly responsive to immunotherapy. What this means If you

Skip to content The CRC Digest ♥ Study explores how ctDNA testing affects fear of recurrence in colorectal cancer survivors Researchers examined the psychosocial impact of circulating tumor DNA testing in early-stage colorectal cancer survivors from three randomized trials, focusing on how this emerging prognostic biomarker influences fear of cancer recurrence.

Skip to content The CRC Digest ♥ Mild to moderate frailty doesn't affect long-term quality of life after colon cancer surgery A study of older adults found that those with mild to moderate frailty at diagnosis experienced similar quality of life, daily functioning, and treatment satisfaction one year after

Skip to content The CRC Digest AI-assisted imaging compared to standard linked color imaging for polyp detection Randomized trial in Brazil compared linked color imaging versus AI-assisted LCI for detecting adenomas and sessile serrated lesions during colonoscopy. (Clinical Endoscopy) This content is informational only and does not constitute medical advice.

Skip to content The CRC Digest Liquid biopsy marker mSEPT9 evaluated for CRC screening and monitoring Research assessed methylated Septin9 as a blood-based biomarker for colorectal cancer diagnosis, recurrence monitoring, and prognosis. (Clinica Chimica Acta) This content is informational only and does not constitute medical advice. Always consult your oncologist